Reference

1. WHO (2004). Deaths by cause, sex and  mortality stratum. World Health Organization. Retrieved on 2007-06-01.
2. Fitmaurice , C. ; Dicker, D . ; Pain , A. ; Hamavid , H. ; Moradi- Lakesh , M. ; MacIntyre , M. F. ; Allen , C. ; Hansen , G. ; Woodbrook, R, ; Wolfe, C. et al The global burden of cancer 2013. JAMA Oncol 2015, 1, 505-527, DOI: 1001/jamaoncol.2015.0735 [Crossref], [PubMed], [CAS], [Google Scholar]
3. Kumar, S. ; Sharma, A. K. ; Lalhlenmawia, H. ; Kumar , D.  Natural Compounds Targeting Major Signaling Pathways I Lung Cancer. Targeting Cellular Signaling Pathways in Lung Diseases 2021, 821-846, DOI: 10.1007/978-981-33-6827-9_37 [Crossref], [Google Scholar]
4. Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small lung cancer. N Eng J Med 377(9) :849-861. https://doi.org/10.1056/NEJMra1703413 (PMID: 28854088)
5. Liu, B, Q., Peto, R., Chen, Z. M. “Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths”. B. Med. J. 1998; 317 (7170): 1411-1422.
6. Greene FL, Page DC, Fleming ID, et al. AJCC Cancer staging manual. 6th ed. New York: Springer-Verlag; 2002. p. 435
7. Thomas KW. Diagnosis and staging of non- small cell lung cancer; UptoDate 2008.
8. Stahel R, Ginsberg R, et al. Staging and prognosis factors in small cell lung cancer: a consensus. report. Lung Cancer 1989;5: 119-26
9. Ginsberg RS, Vokes E, Raben A, Non-small cell cancer of the lung. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott- Raven; 1997:858-911
10. Wynder EL. Tobacco as a cause of lung cancer: some refecltions. Am J Eepidemiol 1997; 146: 687-694. FREE Full Text Google Schola
11. Bailey-Wilson JE, Sellers TA, Elston RC,    et al. Evidence for the main gene effect in the early-onset lung cancer. J La State Med Soc 1993; 145: 157-162. PubMed Google Scholar.
12. Darby S, Hill D, Auvinen A et al. Radon in homes and risk of lung cancer : collaborative analysis of individual data from 13 European case control studies. BMJ 2005; 330 : 223. Abstract/Free Full Text Google Scholar
13. IARC Monographs. Chemical agents and related occupations. Volume 100 F. A review of human carcinogens. Lyon, World Health Organization / IARC 2012. Google Scholar.
14. McCorkle R, Benoliel JQ. Symptom distress, current concerns and mood disturbance after diagnosis of life threatening disease. Soc Sci Med 1983;17:431-438
15. Kaasa S, Mastekaasa A, Thorud E. Toxicity, physical function, and everyday activity reported by patients with inoperable nonsmall cell lung cancer in a randomized clinical trial (chemotherapy versus radiotherapy). Acta Oncol 1988;27:343-349
16. Stabile LP, Davis AL, Gubish CT, et al: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62: 2141-2150, 2002.
17. Katsouyanni K , Pershagen G. Ambient   air pollution exposure and cancer. Cancer Causes Control 1997; 8: 284-91
18. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Sheilds PG and Harris CC: Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutations spectrum in human lung cancer. J Pathol 187: 8-18, 1999
19. Chan SK, Gullick WJ and Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer – search and destroy. Eur J Cancer 42: 17-23, 2006
20. Zochbaucer-Muller S, Minna JD. The biology of lung cancer including potential clinical applications. Chest Surg Clin North Am 2000; 10:691-708.
21. Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, Palcic B, Lam S. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res. 1995; 55:5133-5139. [PubMed] [Google Scholar] [Ref list].
22. Sundaresan V, Heppell-Parton, Coleman N, Miozzo M, Sozzi G, Ball R, Cary N, Hasleton P, Fowler W, Rabbitts P. Somatic genetic changes in lung cancer and precancerous lesions. Ann Oncol. 1995; 6:27-31; discussion 31-2. [PubMed] [Google Scholar] [Ref list]
23. Zhang XC, Wang J, Shao GG, Wang Q, Qu X, Wang B, Moy C, Fan Y, Albertyn Z, Huang X, et al. Comprehensive genonmic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019;10:177
24. Larsen JE, Minna JD. Molecular biology of lung cancer: Clinical implications Clin Chest Med 2011; 32:703-40 [PMC free article] [PubMed] [Google Scholar] [Ref List].
25. Liu P, Morrison C, Wang L, et al. Identification of somatic mutations in non-small cell lung carcinomas using whole exome sequencing. Carcinogenesis 2012; 33:1270-6 [PMC free article] [PubMed] [Google Scholar] [Ref list].
26. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012; 150:1121-34 [PMC free article] [PubMed] [Google Scholar] [Ref list].
27. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers.Cell 2012; 150:1121-34 [PMC free article] [PubMed] [Google Scholar] [Ref list].
28. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4 [PMC free article] [PubMed] [Google Scholar] [Ref list].
29. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25 [PMC free article] [PubMed] [Google Scholar] [Ref list].
30. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic targets in squamous cell lung cancer. Cancer Discov 2011;1:78-89 [PMC free article] [PubMed] [Google Schoar] [Ref list].
31. The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 489(7417):519-25. doi:10.1038/nature11404.
32. George J, LimJS,Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature (2015) 524(7563):47-53. doi:10.1038/nature14664
33. Roby TJ, Swan GE, Sorensen KW, et al. Discriminant analysis of lower respiratory tract components associated with cigarette smoking, based on quantitative sputum cytology. Acta Cytol 1990;34(2): 147-54.
34. Berlin NI. Overview of the NCI cooperative early lung cancer detection program. Cancer 2000;89(11 Suppl):2349-51.
35. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo clinic study. Am Rev Respir Dis 1984;130(4):561-5.
36. Frost JK, Ball WC Jr, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984; 130(4):549-54Lam S, MacAulay CE (1998) Endoscopic localization of preneoplastic lung lesions. in Clinical and biological basis of lung cancer preventive. Eds Martinet Y, Hirsch FR, Martinet N, Vignaud J-M, Mulshine JL (Birkhauser Verlag, Basel), pp 231-237.
37. Kennedy, T.C.; Hirsch, F.R; Miller, Y.E.; Prindiville, S.; Murphy, J.R.; Dempsey, E.; Proudfoot, S.; Bunn, P.A.; Franklin, W.A. A Randomized Study Fluorescence Bronchoscopy versus White-Light Bronchoscopy for Early Detection of Lung Cancer in High Risk Patients. Lung Cancer 2000, 1 (Suppl. S1), 244-245.
38. Cameron, S.J.S.; Lewis, K.E.; Beckmann, M.; Allison, G.G.; Ghosal, R,; Lewis, P.D.; Mur, L.A.J. The Metabolomics Detection of Lung Cancer Biomarkers in Sputum. Lung Cancer 2016, 94,88-95. [CrossRef] [PubMed].
39. Kumar, N.; Shahjaman, M.; Mollah, M.N.H.; Islam, S.M.S.; Hoque, M.A. Serum and Plasma Metabolomics Biomarkers for Lung Cancer. Bioinformation 2017, 13, 202-208. [CrossRef].
40. Cameron, S.J.S.; Lewis, K.E.; Beckmann, M.; Allison, G.G.; Ghosal, R,; Lewis, P.D.; Mur, L.A.J. The Metabolomics Detection of Lung Cancer Biomarkers in Sputum. Lung Cancer 2016, 94,88-95. [CrossRef] [PubMed]
41. Calderón-Santiago, M.; Priego-Capote, F,; Turck, N.; Robin, X.; Jurado- Gámez, B.; Sanchez, J.C.; Luque de Castro, M.D. Human Sweat Metabolomics for Lung Cancer Screening. Anal. Bioanal. Chem. 2015, 407, 5381-5392. [CrossRef] [PubMed].
42. Fogel-Petrovic, M.; Vujcic, S.; Brown, P.J.; Haddox, M.K.; Porter, C.W. Effects of Polyamines, Polyamine Analogs, and Inhibitors of Protein Synthesis on Spermidine-Spermine N1-Acetyltransferase Gene Expression. Biochemistry 1996, 35, 14436-14444. [CrossRef].
43. ZX. Liao, R.R. Komaki, H.D. Thames Jr., H.H. Liu, S.L. Tucker, R. Mohan, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non- small lung cancer receiving concomitant chemoradiotherapy. International Journal of Radiation Oncology Biologic Physics 2010;76(3):775-81.
44. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. International Journal of Radiation Oncology Biology Physics 2007;68:94-102.
45. Karnofsky DA. Chemotherapy of neoplastic  disease: agents of clinical value. N Engl J Med 1948;239:299-305.
46. Rockswold GL, Ramsey HE, Buker GD. The results of treatment of lung cancer by surgery, radiation and chemotherapy at a USPHS hospital. Mil Med 1970;135:362-8.
47. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
48. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22: 3852-9.
49. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007; 12:713-8
50. Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, et al. Stereostatic ablative radiotherapy for operable stage  I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol (2021) 22(10):1448-57. doi: 10.1016/s1470-2045(21)00401-0.
51. Videtic GMM, Hu C, Singh AK, Chang JY, Parker W, Oliver KR, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys (2015) 93 (4):757-64. doi: 10.1016/j.ijrobp.2015.07.2260.
52. Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereostatic body radiotherapy in combination with targeted therapy or immunotherapy: systemic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol (2023) 24(3):e121-32. doi:10.1016/S1470-2045(22)00752-5.
53. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):1-20.doi: 10.1186/s13045-021-01121-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list].
54. Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res 2014; 20: 1067-73.
55. Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutics as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung phase 3 trial. Lancet 2016; 17:822-35.
56. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
57. Dupuy DE. Zagoria RJ. Akerley W, et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000; 174:57-9. [PubMed] [Google Scholar] [Ref list].
58. Bargellini I. Bozzi E. Cioni R. Parentini B. Bartolozzi C. Radiofrequency ablation of lung tumours. Insights into Imaging. 2011;2:567-76. [PMC free article] [PubMed] [Google Scholar] [Ref list].
59. Hiraki T, Gobara H, Iishi T, Sano Y,      Iguchi T, Fujiwara H, et al. Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: Midterm results in 27 patients. J Vasc Interv  Radiol 2007;18:1264-9. [PubMed] [Google Scholar] [Ref list].
60. Goldberg SN, Gazelle GS, Compton CC, McLoud TC. Radiofrequency tissue ablation in the rabbit lung: Efficacy and complications. Acad Radiol. 1995;2:776-84. [PubMed] [Google Scholar] [Ref list]
61. Rose SC, Thistlethwaite PA, Sewell PE, Vance RB. Lung cancer and radiofrequency ablation. J Vasc Interv Radiol. 2006;17:927-51. [PubMed] [Google Scholar] [Ref list].
62. Goldberg SN, Gazelle GS, Compton CC, McLoud TC. Radiofrequency tissue ablation in the rabbit lung: Efficacy and complications. Acad Radiol